Bevacizumab in Cervical Cancer: 5 Years After.
Publication Title
Cancer journal (Sudbury, Mass.)
Document Type
Article
Publication Date
7-1-2018
Abstract
Over the past 5 years, addition of bevacizumab to combination chemotherapy for advanced, recurrent, and persistent cervical cancer has offered prolonged overall and progression-free survival. Since the original press release announcing the survival benefits of this antiangiogenesis therapy, there has been further study of bevacizumab related to quality of life, combination with other agents, use of imaging to evaluate likelihood of response, and development of biosimilars. This review summarizes publications related to bevacizumab use in advanced, recurrent, and persistent cervical cancer over the past 5 years since initial proof of concept of antiangiogenesis therapy and the initial dissemination of information regarding survival benefits of bevacizumab.
Clinical Institute
Women & Children
Clinical Institute
Cancer
Specialty
Obstetrics & Gynecology
Specialty
Oncology
Comments
KS Tewari is Tewari is affiliated with Providence St. Joseph Health, St. Joe Center for Cancer Prevention and Treatment.
Tewari is PSJH, From St. Joe Center for Cancer Prevention and Treatment